The histamine receptor family offers a striking example of how a single small molecule can orchestrate profoundly different physiological outcomes depending on which of its four recognized receptor subtypes it engages. Histamine itself binds to all four receptor classes with nanomolar affinity, yet the cellular context of each receptor dictates vastly different consequences. At the H3 receptor, histamine functions predominantly as a neuromodulator, while at the H4 receptor it acts as a recruiter and modulator of immune cell behavior. This duality has made the receptor pair an attractive testing ground for medicinal chemistry programs that aim to disentangle central nervous system effects from peripheral inflammatory ones. The structural similarity between the two receptors, however, makes this disentanglement far from trivial, and it is precisely this challenge that scaffold hopping approaches are designed to address.

The concept of scaffold hopping, though formally named only in recent decades, has been an implicit part of medicinal chemistry practice since the earliest days of antihistamine development. The transition from first-generation ethanolamine antihistamines such as diphenhydramine to tricyclic phenothiazines like promethazine represented an early, if unintentional, exercise in changing the molecular framework while preserving the pharmacophoric elements needed for receptor binding. Subsequent refinements produced second-generation antihistamines with markedly reduced sedative liability, and the same structural exploration also yielded compounds with entirely different primary indications, including antipsychotic agents that retain antihistamine activity as a side effect. These historical examples illustrate a central principle: changing the scaffold can alter absorption, distribution, metabolism, and off-target profiles without necessarily abolishing the interaction with the intended receptor, provided the key binding features are retained.

For the H3 and H4 receptors specifically, the conserved amino acid residues that anchor the endogenous ligand provide a useful starting point for rational design. The negatively charged aspartate residue located in the third transmembrane helix, conventionally labeled Asp3.32, forms an ionic interaction with the protonated amine of histamine and of virtually all synthetic agonists and antagonists directed at these receptors. A second conserved residue, glutamate at position 5.46 in the fifth transmembrane helix, engages the imidazole ring of histamine through hydrogen bonding. Ligands that lack an imidazole group, such as the non-imidazole H3 antagonist FUB 661, must find alternative ways to occupy this region of the binding pocket or dispense with that interaction altogether, often compensating with additional hydrophobic or polar contacts elsewhere. Understanding which interactions are dispensable and which are essential is one of the central questions that structure-activity relationship studies attempt to answer.

The distinction between ligands that preferentially engage H3 versus H4 receptors has historically tracked with molecular shape and conformational flexibility. H3 receptor ligands tend to tolerate, and often benefit from, a degree of conformational freedom, with longer linker chains connecting the aromatic recognition element to the basic amine. This flexibility presumably allows the ligand to adopt binding poses that accommodate the slightly different geometry of the H3 orthosteric site. H4 receptor ligands, by contrast, are frequently more compact and rigid, with the pharmacophoric elements held in a tighter spatial arrangement. The prototypical H4 antagonist JNJ-7777120 exemplifies this compact architecture, and its high selectivity over H3 has made it a reference compound for the field. The observation that rigidifying or compacting a scaffold can shift selectivity toward H4, while extending and flexing it can favor H3, provides a practical design heuristic that the present work exploits systematically.

Ring opening as a scaffold hopping maneuver deserves particular attention because it occupies an intermediate position on the spectrum of structural change. Unlike wholesale heterocycle replacement, which can dramatically alter electronic properties and binding geometry, ring opening preserves much of the spatial relationship between substituents while introducing conformational freedom and often improving synthetic accessibility. When applied to a rigid bicyclic or fused-ring chemotype, ring opening converts a constrained framework into an acyclic analogue whose torsional angles can be probed systematically through homologation, that is, the stepwise insertion or removal of methylene units in the linker. Each homologation step shifts the distance between the aromatic group and the basic nitrogen, allowing the medicinal chemist to map the optimal spacing for receptor affinity with fine granularity.

Bioisosteric replacement, the third strategy employed in this study, complements the other two by addressing the electronic and hydrogen-bonding dimensions of ligand-receptor recognition. Replacing an amide linker with a urea, or vice versa, changes the hydrogen-bond donor and acceptor pattern while keeping the overall molecular dimensions roughly constant. The literature on H4 receptor ligands offers instructive cautionary examples here: urea derivatives designed to preserve the hydrogen-bond donor present in the indole NH of JNJ-7777120 analogues have generally shown disappointing H4 affinity, suggesting that the precise geometry and context of that donor, not merely its presence, matters for productive binding. Amide-linked analogues remain comparatively underexplored, which makes the systematic evaluation of anilide and benzylamide scaffolds in this work a meaningful contribution to filling that gap in the SAR landscape.

The reported affinities themselves tell a coherent story about how these structural manipulations played out empirically. Within the LINS05-derived set, which descends from more flexible chemotypes, the best compound achieved a pKi of 6.27 at H3, corresponding to a submicromolar dissociation constant, with measurable selectivity over H4. Within the LINS01-derived set, built from a more compact starting point, most compounds reached nanomolar H3 affinity, and the standout compound 11 attained a pKi of 7.02 with good H3 selectivity. Interestingly, the same series also yielded compound 14, which inverted the selectivity profile, showing its best affinity at H4 with a pKi of 5.23 while retaining a pKi of 6.27 at H3. This inversion within a single congener series is scientifically valuable because it demonstrates that relatively modest structural changes can redirect selectivity between two closely related paralogs, offering a starting point for the design of H4-selective probes from a chemotype that historically favored H3.

It is worth contextualizing what these pKi values mean in practical terms. A pKi of 7.02 corresponds to a Ki of roughly 95 nanomolar, while a pKi of 6.27 corresponds to approximately 540 nanomolar. These affinities fall short of the best-in-class H3 antagonists reported in the literature, some of which achieve low-nanomolar or even subnanomolar binding, and they are well below the pKi of 8.3 exhibited by JNJ-7777120 at H4. However, the purpose of an exploratory scaffold hopping campaign is not typically to produce a clinical candidate on the first pass but rather to establish that a new framework can engage the target at all and to generate a preliminary SAR map that guides subsequent optimization. Viewed through that lens, the identification of multiple novel frameworks with measurable, reproducible affinity constitutes a successful outcome, and the nanomolar H3 affinity of compound 11 provides a credible launching point for affinity maturation.

The computational component of the study, molecular docking, serves as the interpretive bridge between synthetic chemistry and receptor pharmacology. Docking the synthesized compounds into homology or crystallographic models of H3 and H4 allows the researchers to propose specific interaction patterns, such as the salt bridge between the protonated amine and Asp3.32, aromatic stacking or hydrophobic contacts within the lipophilic pocket, and hydrogen bonds involving the linker region. By comparing docked poses across the congener series, one can rationalize why a particular homologue outperforms its neighbors, or why a bioisosteric replacement diminished affinity. Such rationalizations remain hypotheses until tested by further synthesis or by higher-resolution structural methods, but they convert raw affinity data into actionable design principles for the next synthetic cycle.

Looking forward, several avenues naturally follow from this work. The most potent H3-selective compound invites optimization through additional homologation and substituent variation on the aromatic ring, with the goal of pushing affinity into the low-nanomolar range while maintaining or improving selectivity. The H4-preferring compound 14 suggests that the LINS01-derived scaffold, despite its origins, can be steered toward the immune-cell receptor, and targeted modifications to the linker region might amplify this preference. Beyond affinity optimization, subsequent studies would need to characterize functional activity, determining whether these ligands act as neutral antagonists, inverse agonists, or partial agonists, since H3 and H4 receptors are constitutively active and inverse agonism carries distinct therapeutic implications. Pharmacokinetic properties, including brain penetration for H3-directed candidates and metabolic stability for both directions, will ultimately determine whether any of these novel chemotypes can progress beyond the exploratory stage. In the meantime, the systematic SAR data generated here enriches the collective knowledge base for a receptor pair whose therapeutic potential, spanning narcolepsy, cognitive disorders, obesity, and inflammatory disease, continues to motivate sustained medicinal chemistry attention.

Subject of Research: …

Article Title: Exploratory scaffold hopping strategies led to identification of novel histamine H3 and H4 receptor ligands

Article References: Exploratory scaffold hopping strategies led to identification of novel histamine H3 and H4 receptor ligands. (n.d.). https://doi.org/10.3389/fddsv.2026.1944403

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1944403

Keywords: scaffold hopping, histamine H3 receptor, histamine H4 receptor, bioisosterism, structure-activity relationships, molecular docking, drug discovery, piperazine ligands, benzofuran derivatives, ligand efficiency, medicinal chemistry, radioligand binding assays